<?xml version="1.0" encoding="UTF-8"?>
<p id="Par62">At the moment, all international rheumatology societies, including ACR (American College of Rheumatology), EULAR (European League Against Rheumatism), and PReS (Pediatric Rheumatology European Society) recommend continuation of immunosuppressive treatment in patients with rheumatic diseases. Previous studies on SLE and RA patients provided data on the increased rate of infections in cases of high disease activity [
 <xref ref-type="bibr" rid="CR103">103</xref>, 
 <xref ref-type="bibr" rid="CR104">104</xref>]. Thus, the primary aim should be an effective disease control in our patients with rheumatic diseases.
</p>
